Talis Biomedical Corp Stock Cash Flow From Operations
Talis Biomedical Corp fundamentals help investors to digest information that contributes to Talis Biomedical's financial success or failures. It also enables traders to predict the movement of Talis Pink Sheet. The fundamental analysis module provides a way to measure Talis Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Talis Biomedical pink sheet.
Talis |
Talis Biomedical Corp Company Cash Flow From Operations Analysis
Talis Biomedical's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Talis Biomedical Cash Flow From Operations | (53.24 M) |
Most of Talis Biomedical's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Talis Biomedical Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Talis Biomedical Corp has (53.24 Million) in Cash Flow From Operations. This is 110.1% lower than that of the Health Care Equipment & Supplies sector and 114.57% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 105.48% higher than that of the company.
Talis Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Talis Biomedical's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Talis Biomedical could also be used in its relative valuation, which is a method of valuing Talis Biomedical by comparing valuation metrics of similar companies.Talis Biomedical is currently under evaluation in cash flow from operations category among its peers.
Talis Fundamentals
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (113.60) % | ||||
| Current Valuation | (38.24 M) | ||||
| Shares Outstanding | 1.82 M | ||||
| Shares Owned By Insiders | 8.30 % | ||||
| Shares Owned By Institutions | 52.15 % | ||||
| Number Of Shares Shorted | 17.96 K | ||||
| Price To Book | 0.06 X | ||||
| Price To Sales | 19.57 X | ||||
| Revenue | 412 K | ||||
| Gross Profit | (149.4 M) | ||||
| EBITDA | (60.7 M) | ||||
| Net Income | (62.01 M) | ||||
| Cash And Equivalents | 165.37 M | ||||
| Cash Per Share | 6.21 X | ||||
| Total Debt | 19.67 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 12.51 X | ||||
| Book Value Per Share | 26.68 X | ||||
| Cash Flow From Operations | (53.24 M) | ||||
| Short Ratio | 0.59 X | ||||
| Earnings Per Share | (28.02) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 99 | ||||
| Beta | 1.62 | ||||
| Market Capitalization | 7.98 M | ||||
| Total Asset | 98.34 M | ||||
| Retained Earnings | (539.96 M) | ||||
| Working Capital | 68.91 M | ||||
| Net Asset | 98.34 M |
About Talis Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Talis Biomedical Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Talis Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Talis Biomedical Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Talis Pink Sheet
If you are still planning to invest in Talis Biomedical Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talis Biomedical's history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |